É«¿Ø´«Ã½

Sticker Shock: New Research Shows an Average List Price Increase of Over 200% for Top Part D Drugs

Research released by AARP’s Public Policy Institute (PPI), list prices for the top 25 Medicare Part D drugs have increased by an average of 226%.

Local Leaders, Consumers, and Media Praise the Value of Employer-Provided Coverage

Getting the Facts: Drug Companies Increasingly Using Patent Games to Avoid Competition

A recent article published by STAT highlights how Big Pharma is using continuation patents to keep lower-cost generic drugs from reaching the market.

Americans Agree: Fixed Indemnity Plans Are Important for Financial Security and Peace of Mind

New Health Affairs Study: Competition In Pharmaceuticals Leads to Lower Prices, Reduced Drug Spending

A study published in Health Affairs found that new brand-name pharmaceutical competition resulted in decreases in net prices of existing drugs.

One Set of Rules Means Lower Costs for Health Care

And why it matters for employer-provided coverage.